Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for X4 Pharmaceuticals, Inc. (XFOR : NSDQ)
 
 • Company Description   
X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States.

Number of Employees: 143

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.00 Daily Weekly Monthly
20 Day Moving Average: 823,805 shares
Shares Outstanding: 87.44 (millions)
Market Capitalization: $349.75 (millions)
Beta: 0.41
52 Week High: $24.43
52 Week Low: $1.35
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.26% 5.44%
12 Week 16.62% 14.74%
Year To Date 0.00% 0.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
61 North Beacon Street 4th Floor
-
Boston,MA 02134
USA		 ph: 857-529-8300
fax: -		 daniel@lifesciadvisors.com http://www.x4pharma.com
 
 • General Corporate Information   
Officers
Paula Ragan - President and Chief Executive Officer
Michael S. Wyzga - Chairman
Adam S. Mostafa - Chief Financial Officer and Treasurer
William E. Aliski - Director
Gary J. Bridger - Director

Peer Information
X4 Pharmaceuticals, Inc. (CORR.)
X4 Pharmaceuticals, Inc. (RSPI)
X4 Pharmaceuticals, Inc. (CGXP)
X4 Pharmaceuticals, Inc. (BGEN)
X4 Pharmaceuticals, Inc. (GTBP)
X4 Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98420X202
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/24/26
Share - Related Items
Shares Outstanding: 87.44
Most Recent Split Date: 4.00 (0.03:1)
Beta: 0.41
Market Capitalization: $349.75 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.08 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/24/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.63
Price/Cash Flow: -
Price / Sales: 10.29
EPS Growth
vs. Year Ago Period: 87.23%
vs. Previous Quarter: 80.12%
Sales Growth
vs. Year Ago Period: 215.18%
vs. Previous Quarter: -10.54%
ROE
12/31/25 - -
09/30/25 - -343.67
06/30/25 - -375.31
ROA
12/31/25 - -
09/30/25 - -69.77
06/30/25 - -72.87
Current Ratio
12/31/25 - -
09/30/25 - 5.65
06/30/25 - 3.19
Quick Ratio
12/31/25 - -
09/30/25 - 5.48
06/30/25 - 3.05
Operating Margin
12/31/25 - -
09/30/25 - -279.86
06/30/25 - -311.15
Net Margin
12/31/25 - -
09/30/25 - -279.86
06/30/25 - -311.15
Pre-Tax Margin
12/31/25 - -
09/30/25 - -278.98
06/30/25 - -310.10
Book Value
12/31/25 - -
09/30/25 - 2.45
06/30/25 - 0.50
Inventory Turnover
12/31/25 - -
09/30/25 - 1.73
06/30/25 - 1.93
Debt-to-Equity
12/31/25 - -
09/30/25 - 1.23
06/30/25 - 19.10
Debt-to-Capital
12/31/25 - -
09/30/25 - 55.24
06/30/25 - 95.03
 

Powered by Zacks Investment Research ©